Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.

doi:10.18632/oncotarget.13062

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.

Oncotarget - 22 Nov 2016

Wei Lei, Chintala Sreenivasulu, Ciamporcero Eric, Ramakrishnan Swathi, Elbanna May, Wang Jianmin, Hu Qiang, Glenn Sean T, Murakami Mitsuko, Liu Lu, Gomez Eduardo Cortes, Sun Yuchen, Conroy Jacob, Miles Kiersten Marie, Malathi Kullappan, Ramaiah Sudha, Anbarasu Anand, Woloszynska-Read Anna, Johnson Candace S, Conroy Jeffrey, Liu Song, Morrison Carl D, Pili Roberto

Abstract excerpt

PURPOSE: Effective systemic therapeutic options are limited for bladder cancer. In this preclinical study we tested whether bladder cancer gene alterations may be predictive of treatment response. EXPERIMENTAL DESIGN: We performed genomic profiling of two bladder cancer patient derived tumor xenografts (PDX). We optimized the exome sequence analysis method to overcome the mouse genome interference. RESULTS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to TOR Serine-Threonine Kinases

Share to Urinary Bladder Neoplasms

Share to Whole Genome Sequencing

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27823983
DOI: 10.18632/oncotarget.13062
PMCID: PMC5363516

Genes

BRCA2
CASP8
MLH1
TLE4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.PMID 27823983Read ↗

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapiesSemantic proximity Read ↗

Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.Semantic proximity Read ↗

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.Semantic proximity Read ↗

Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.Semantic proximity Read ↗

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder CancerSemantic proximity Read ↗

Molecular Mechanisms of Targeted Therapy Resistance in Genitourinary Tumors: A Path to New Therapeutic HorizonsSemantic proximity Read ↗

Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors.Semantic proximity Read ↗

Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancerSemantic proximity Read ↗

The geriatrics and genetics behind bladder cancer.Semantic proximity Read ↗

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.Semantic proximity Read ↗

Personalized <i>in-silico</i> drug response prediction based on the genetic landscape of muscle-invasive bladder cancerSemantic proximity Read ↗

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.